Use search to browse all 100+ peptides
LY3437943, LY-3437943
A synthetic peptide acting as a triple agonist for GLP-1, GIP, and glucagon receptors, designed for treating obesity and type 2 diabetes by promoting weight loss and glycemic control.
Zhou. Qingtong Q; Li. Guanyi G; Hang. Kaini K; Li. Jie J; Yang. Dehua D; Wang. Ming-Wei MW
Retatrutide is a new drug that hits several targets at once and has shown very strong weight‑loss and blood‑sugar benefits in clinical studies, similar to tirzepatide. It works better than older single‑target drugs but can cause stomach upset and people may regain weight after stopping it.
Yang. Yucheng Y; He. Liyun L; Han. Shumeng S; Yang. Na N; Liu. Yiwen Y; Wang. Xuechen X; Li. Ziyi Z;...
A big review of studies found that women tend to lose a bit more weight than men when they take GLP‑1 drugs like dulaglutide, semaglutide, or the newer retatrutide. The difference gets bigger the more total weight is lost, especially when the drug is used specifically for obesity. Other factors like dose, treatment length, or starting weight didn’t change this gender gap.
Kokkorakis. Michail M; Chakhtoura. Marlene M; Rhayem. Caline C; Al Rifai. Jana J; Ghezzawi. Malak M;...
A new wave of obesity drugs is being tested, including a combo peptide called retatrutide that hits three hormone pathways (GLP‑1, GIP, and glucagon). Early trials of similar hormone‑based drugs have shown people lose about 7‑24% of their weight, and many of these new agents are still in phase 2 or 3 studies. While the review doesn’t give exact results for retatrutide yet, it highlights that these multi‑target peptides are the most promising part of the current obesity drug pipeline.
Naeem. Muhammad M; Imran. Laiba L; Banatwala. Umm E Salma Shabbar UESS
Retatrutide is a new drug that mimics three gut hormones and has shown strong weight‑loss results in early human studies. It appears to work better at higher doses, has a good safety record so far, and could become a powerful tool for people trying to lose fat, but more research is still needed before it can be used widely.
Cho. Yun Kyung YK; Jung. Chang Hee CH
Retatrutide is a new triple‑hormone peptide that hits GLP‑1, GIP and glucagon at once. Early studies show it can cause big drops in weight and blood sugar, plus possible liver and heart benefits, acting like the hormone mix after bariatric surgery. It’s still in clinical trials, so it isn’t something you can use yet, but it points to the next generation of powerful weight‑loss drugs.
Viebahn. Greta Karoline GK; Khurana. Amit A; Freund. Linton L; Chilin-Fuentes. Daisy D; Jepsen. Kris...
In a short (31‑day) mouse study that mimics human fatty liver disease, the drug retatrutide lowered body weight, liver enzymes, fat buildup, cholesterol, and inflammation in the liver, especially in female mice. This suggests the peptide could help treat metabolic‑related liver damage, but the evidence is still limited to animals.
Le Roux. Carel C; Mondoh. Alvin A
This review looks at drugs that stick to the GLP‑1 receptor to help people lose weight. It compares several of them—retatrutide, CagriSema, survudotide, tirzepatide, semaglutide, and liraglutide—and finds that retatrutide seems to work best so far, while all of them appear fairly safe in the short term. Long‑term benefits and exact dosing still need more study.
Yan. Kangling K; Yu. Haichuan H; Blaise. Benoît B
A recent analysis of many diabetes drug trials found that the experimental peptide retatrutide caused the biggest drop in body weight (about 8.6% on average) compared to other drugs, while tirzepatide was best at lowering blood sugar. However, the studies were small and short, so we still need more proof before recommending these drugs for everyday use.
Wen. Yi Y; Lemen. Deven D; Lin. Yanzhu Y; Chen. Yan Q YQ; Regmi. Ajit A; Roell. William C WC; Thomas...
Retatrutide, a drug that hits three gut hormone receptors (GIP, GLP‑1, and glucagon), was shown in phase‑2 studies to lower blood fats (triglycerides and LDL cholesterol) by cutting down a protein complex called ANGPTL3/8. The drop in this protein matched the drop in the bad lipids, and lab work showed the glucagon part of the drug was key to this effect.
Ullah. Mohammad Iftekhar MI; Tamanna. Sadeka S
Obesity is a massive health problem that shortens life and costs trillions of dollars. Old weight‑loss drugs were weak and had bad side effects, but newer GLP‑1 medicines like semaglutide and tirzepatide can cut 15‑25% of body weight and lower heart disease and diabetes risk. A next‑generation peptide called retatrutide, which hits three receptors, looks promising for better tolerance and keeping muscle, maybe even rivaling bariatric surgery, though it’s still early and pricey.
Chong. Keong K; Chang. Jack Keng-Jui JK; Chuang. Lee-Ming LM
The article reviews new diabetes drugs that not only lower blood sugar but also help with weight loss and protect the heart and kidneys. It highlights three groups: SGLT2 inhibitors, which cut heart‑failure and kidney risk; GLP‑1 agonists, which improve glucose control, aid weight loss, and lower cardiovascular events; and newer drugs that hit both GIP and GLP‑1 receptors, offering even better glucose control and more weight loss than GLP‑1 alone. These insights point to newer options that could be useful for people looking to manage diabetes, lose weight, or boost overall metabolic health, but they still require a doctor’s prescription and monitoring.
Ray. Avik A
Retatrutide is a new drug that hits three gut hormone receptors and in early trials helped people lose a lot of weight and lower blood sugar, especially at higher doses, but it also caused stomach upset and raised heart rate, with some mild heart rhythm issues, so more safety data are needed before regular use.
Wang. Shuang S; Liu. Yun Y; Yan. Zhiming Z; Huang. Xianxian X; Liao. Yonghe Y; Tang. Chunli C; Jing....
Scientists designed a new peptide that hits three hormone receptors (GLP‑1, glucagon, and GIP) but hits the GIP receptor less strongly. It caused weight loss as good as the drug tirzepatide and worked about as well as retatrutide, even though its GIP activity was weaker. This shows you don’t need super‑strong activation of all three receptors to get big metabolic benefits.
Windram. McKinley M; Lovelock. Dennis F DF; Carew. Joseph M JM; Krieman. Caroline G CG; Hendershot....
In rats, giving drugs that activate GLP‑1, GIP, and glucagon receptors – including the newer peptide retatrutide – makes the animals less able to sense alcohol’s effects. This effect lasts while the drug is given and fades a few days after stopping.
Wen. Jimmy J; Nadora. Denise D; Bernstein. Ethan E; How-Volkman. Christiane C; Truong. Alina A; Joy....
A big review of 62 trials looked at whether drugs that act like GLP‑1 (including the newer peptide retatrutide) raise the chances of getting pancreatitis or pancreatic cancer. Overall, there was a modest rise in pancreatitis risk, but this disappeared when the data were split by whether people were also taking other medicines. The chance of pancreatic cancer didn’t go up overall, though a small increase showed up in the subgroup that used background meds.
Takrori. Ehab E; Peshin. Supriya S; Singal. Sakshi S
A review of 12 studies shows that anti‑obesity drugs, especially GLP‑1 agonists like semaglutide, tirzepatide, and the newer peptide retatrutide, often cause stomach‑related side effects such as nausea, vomiting, diarrhea, and constipation. These effects are usually mild to moderate but can make people stop the medication. Careful dose‑escalation and early counseling can help reduce these problems.
Abdelrahman. Riad Mohammed RM; Musa. Taha Hussein TH; Arbab. Ismail Adam IA; Suliman. Mohsen Hussein...
GLP‑1 receptor agonists like liraglutide, semaglutide and tirzepatide are already proven to help people lose weight and control blood sugar. New drugs such as retatrutide are in late‑stage trials and could work even better or be useful for other health problems like fatty liver, kidney disease and heart failure. The field is also moving toward longer‑acting shots, combo pills and digital tools that make dosing easier, while cheaper generic versions are starting to appear.
Ciardullo. Stefano S; Muraca. Emanuele E; Vergani. Michela M; Invernizzi. Pietro P; Perseghin. Gianl...
This review says that drugs originally made for diabetes and obesity—especially peptide drugs that hit multiple hormone receptors like tirzepatide and retatrutide—are being tested to treat fatty liver disease (NAFLD/MASLD). It also notes that liver‑focused medicines are in late‑stage trials and that mixing metabolic and liver‑targeted drugs might work best.
Drucker. Daniel J DJ
This review talks about how drugs that activate the GLP‑1 receptor (like the popular weight‑loss meds) improve diabetes, obesity, heart and kidney health, and are being tested for many other conditions. Newer versions, such as tirzepatide, retatrutide and others, add extra actions on GIP or glucagon receptors, which could boost weight loss and metabolic benefits. The paper also lists safety issues to watch – muscle strength, bone health, gut motility, pancreas and cancer risks – so you can weigh the pros and cons before trying these powerful peptides.
Li. Meng M; Cui. Man M; Li. Guoxia G; Liu. Yueqiu Y; Xu. Yunsheng Y; Eftekhar. Seyed Parsa SP; Ala....
The article explains how obesity starts a cascade that leads to fatty liver and clogged arteries, and how losing weight can reverse these problems. It highlights that new drugs like retatrutide hit several of the underlying pathways at once, giving bigger weight‑loss results and better liver and heart health than older treatments.